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ARTICLE
Mapping Trait Loci by Use of Inferred Ancestral Recombination
Graphs
Mark J. Minichiello and Richard Durbin
Large-scale association studies are being undertaken with the hope of uncovering the genetic determinants of complex
disease. We describe a computationally efﬁcient method for inferring genealogies from population genotype data and
show how these genealogies can be used to ﬁne map disease loci and interpret association signals. These genealogies
take the form of the ancestral recombination graph (ARG). The ARG deﬁnes a genealogical tree for each locus, and, as
one moves along the chromosome, the topologies of consecutive trees shift according to the impact of historical recom-
bination events. There are two stages to our analysis. First, we infer plausible ARGs, using a heuristic algorithm, which
can handle unphased and missing data and is fast enough to be applied to large-scale studies. Second, we test the
genealogical tree at each locus for a clustering of the disease cases beneath a branch, suggesting that a causative mutation
occurred on that branch. Since the true ARG is unknown, we average this analysis over an ensemble of inferred ARGs.
We have characterized the performance of our method across a wide range of simulated disease models. Compared with
simpler tests, our method gives increased accuracy in positioning untyped causative loci and can also be used to estimate
the frequencies of untyped causative alleles. We have applied our method to Ueda et al.’s association study of CTLA4
and Graves disease, showing how it can be used to dissect the association signal, giving potentially interesting results
of allelic heterogeneity and interaction. Similar approaches analyzing an ensemble of ARGs inferred using our method
may be applicable to many other problems of inference from population genotype data.
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Unraveling the genetic basis of complex disease is one of
the main goals of human genetics. In the case-control
association study design,1,2 nonfamilial individuals are ge-
notyped for a panel of SNPs that capture most but not all
of the genetic variation in a population. Each individual
is labeled as either a “case” (affected by the disease) or as
a “control” (unaffected), and, by analyzing the segregation
of SNP alleles between cases and controls, it is possible to
identify loci with statistical association with the disease.
One of the simplest analyses for case-control data is
Pearson’s test applied to each marker. This tests for non-2x
independence between genotype and phenotype, and, in
certain circumstances, it will successfully identify disease
associations—such as when causative polymorphisms are
typed or are in strong linkage disequilibrium (LD) with
typed markers.3,4 But, by the testing of each marker in-
dependently, information about the population history is
discarded (in particular, information about the coinher-
itance of markers) that, if exploited, can yield a substantial
increase in power.
A potentially more powerful approach is to interpret the
pattern of variation by considering the evolutionary pro-
cesses that produced it.5,6 In this article, we present an
algorithm for reconstructing the genealogical history of a
population sample and show how these genealogies can
be used to ﬁne map disease loci. Additionally, we use the
genealogies to dissect the association signal—estimating
the frequencies of untyped polymorphisms and searching
for allelic heterogeneity and epistasis.
The formalism we use for representing these genealogies
is the ancestral recombination graph (ARG).7 For a pop-
ulation of chromosome sequences, the ARG describes how
they are related to each other—through mutation, recom-
bination, and coalescence—back to a common ancestor
(ﬁg. 1A). Note that we are using the term “ARG” to mean
the data structure for representing genealogical histories.
The distribution of these under the Wright-Fisher model
with recombination is described by a stochastic process
called the “coalescent-with-recombination” model.7–10
For each position on the chromosome, there is a ge-
nealogical tree, called a “marginal tree,” embedded in the
ARG. As one moves along the chromosome, the topologies
of consecutive marginal trees shift according to the impact
of historical recombination events (ﬁg. 1B and 1C). In this
way, historical recombination events deﬁne the chromo-
somal region that each marginal tree spans, and, since
many recombination events have occurred in population
history, the resolution is very ﬁne.
If there is a disease-predisposing mutation at a particular
chromosomal location, it would have occurred on some
internal branch of the marginal tree at that location. So,
one way to ﬁnd disease associations is to scan across the
marginal trees, looking for those with branches that dis-
criminate well between cases and controls—that is, that
have a large number of cases beneath them and signiﬁ-
cantly fewer controls. Such a clustering of the cases un-
derneath a branch suggests that a causativemutationarose
on that branch.
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Figure 1. The ARG. A, Example ARG for four chromosome se-
quences. The sequences label the leaves of the ARG and are written
as strings of 0s and 1s (coding SNP alleles). Moving backward in
time (up the ARG), one ﬁrst encounters a mutation. A mutation
is denoted by a black dot and a number specifying its marker
position. The second event is a recombination between markers 2
and 3. As one works backward in time, this corresponds to splitting
a lineage into two, with the alleles at positions 1 and 2 following
the left lineage and the allele at position 3 following the right
lineage. After this is a coalescence, merging two lineages into
one, and so on, to the grand common ancestor. B, Marginal tree
for the SNPs at positions 1 and 2. C, Marginal tree for the SNP at
position 3. To test a marginal tree for disease association, mu-
tations are dropped onto each of the branches in turn, deﬁning
hypothetical allelic states of the leaves, which can then be tested
for statistical association with the phenotype. The black dot la-
beled “2” best segregates the cases (D) from the controls (U) and
would be identiﬁed as the most likely causative mutation event.
D–G, Logic behind the ARG inference algorithm. D, The two se-
quences have a shared tract over the region . E, To coalesce[1,2]
over the tract region, we must add a recombination breakpoint to
the right of it—that is, between positions 2 and 3. This results
in two parent sequences. F, We let undeﬁned material (denoted
by ) coalesce with anything. We can now coalesce the left re-·
combination parent and the other sequence. G, We can add a
mutation.
If the true ARG were known, it would provide the op-
timal amount of information for mapping—no extra in-
formation would be available from the genotypes. Not
only would disease-associated regions be identiﬁed, but
the ARG would give the ages of the causative mutations,
would specify the haplotypic background of those mu-
tations, and so forth. It would also be possible to optimally
impute missing data. But, unfortunately, the true ARG is
unknowable, and inference under the coalescent-with-
recombination model has proven computationally pro-
hibitive. This is in part because there are inﬁnitely many
ARGs compatible with any set of genotype data, and very
many of these are of comparable likelihood.11,12
The difﬁculties involved in coalescent-based inference
have partly motivated the development of faster haplo-
type-clustering methods.13–17 These cluster the haplotype
sequences (for small nonrecombining regions) and per-
form statistical tests on these clusters. The clustering hi-
erarchy is often organized as a cladogram, which is as-
sumed to approximate the marginal tree for that region.
However, compared with the ARG, cladograms are a coarse
approximation of population evolution, and there is often
difﬁculty in modeling the relationships between similar
haplotypes and in handling rare haplotypes. Additionally,
it is often assumed that haplotypes are observed directly
and that one can deﬁne nonrecombining haplotype
blocks, which, in general, is not the case.
We have developed an ARG-based mapping method
that has computational efﬁciency nearing that of haplo-
type-clustering methods. We achieve this by using a heu-
ristic approach for ARG inference and are thereby able to
construct ARGs for thousands of individuals typed for
hundreds of SNPs; this is sufﬁciently fast that the analysis
may be windowed over thewhole genome, ﬁtting the scale
of proposed large-scale case-control studies. However, in
this article, we focus our attention on ﬁne mapping and
interpretation of a signal at a potentially associated locus,
in part because there are currently no publicly available
genomewide-association-study data sets, experimental or
simulated. Because the algorithm is heuristic, we do not
claim to sample ARGs from the coalescent-with-recom-
bination model; instead, we suggest that we infer plausible
ARGs, a claim that can be tested by seeing how well these
ARGs infer properties of causative polymorphisms. In this
way, our method ﬁlls the gap between methods that are
based on more-sophisticated coalescent models18–20 but
require prohibitive computation and haplotype-based
methods that model less precisely the structure and evo-
lution of a disease locus.
Methods
A related problem to constructing plausible ARGs is that of con-
structing minimal ARGs21–23—that is, those with the smallest
number of recombination events required to derive a sample of
sequences. An algorithm that is similar to our ARG inference
method has been developed independently for this problem.24
Our emphasis is, however, on inference of plausible ARGs rather
than minimal ones.
To develop an intuition for how our ARG inference algorithm
works, we will give an informal description in two stages—ﬁrst,
by describing a way to construct genealogical trees for nonre-
combining chromosome sequences and then by extending this
to include recombination, so that ARGs can be constructed for
any set of sequences.
When the sequences are nonrecombining, we only need to use
coalescences and mutations to describe their genealogy, and there
are efﬁcient algorithms for this.25,26 Working backward in time,
two haplotype sequences can coalesce into a parent sequence
(that is, their lineages merge into one) only if they are identical.
Since the goal of our algorithm is to coalesce back to a single
common ancestor, we perform coalescences whenever possible.
Unless all the sequences are identical, we will also need to infer
mutation events and remove mutant alleles from ancestral se-
quences. We will assume the inﬁnite-sites model throughout,
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which stipulates that there are no back or recurrent mutations.
Consequently, a mutant allele can be removed from a set of an-
cestral sequences only if it occurs on exactly one of those se-
quences. By performance of mutations and coalescences as de-
scribed, ancestral populations are deﬁned, and, if there were no
recombinations, it will be possible to coalesce back to a single
common ancestor.
If recombination did occur, it may not be possible to construct
a tree for the sequenced region, and, instead, an ARG must be
inferred. To infer recombination events, our algorithm looks for
pairs of sequences that are identical over a contiguous region (ﬁg.
1D–1G). We assume that such a shared tract is inherited intact
from an ancestor and that the sequence mismatches at either end
of the tract were caused by historical mutation or recombination
events. If recombination events are added at both ends of a shared
tract, the tract becomes decoupled from the genetic material to
the left and right of it and is then free to coalesce.
To understand this, consider working backward in time, putting
a recombination event on a sequence. This results in two parental
sequences, a left parent and a right parent, that are only deﬁned
to the left and right of the recombination breakpoint, respec-
tively—they failed to pass on the rest of their genetic material to
the next generation. Since undeﬁned regions have no constraint
on what they can coalesce with, the number of mismatching
alleles preventing a coalescence is reduced, possibly to zero. By
incorporating recombination into genealogy construction, it is
always possible to construct an ARG that coalesces back to a single
common ancestor.
What follows is a more detailed description of the algorithm.
It can infer ARGs from population data with missing genotypes
and unknown haplotype phase, although, for ease of exposition,
we initially describe the simpler case of perfect phase-knowndata.
ARG Inference Algorithm
The algorithm works backward in time from the contemporary,
typed population of chromosome sequences to a single ancestor
sequence. Each step back in time, accomplished with a recom-
bination, mutation, or coalescence, deﬁnes an ancestral popu-
lation of sequences. We denote the set of sequences at time T as
, and the sequences are, in the phase-known case, strings ofST
length m from the alphabet , where m is the number of{0,1, · }
markers, 0 is one of the SNP alleles, 1 is another allele, and “ ”·
denotes an undeﬁned allele—undeﬁned because it was not in-
herited by any sequences in the contemporary, typed population.
The allelic state of a SNP on sequence C is denoted , where iC[i]
is the marker position, numbered from 1, so . We deﬁne1  i  m
if and only if , or , or .C [i] ∼ C [i] C [i] p C [i] C [i] p · C [i] p ·1 2 1 2 1 2
We deﬁne a complement operator, , such that, if , then¬ C[i] p 0
and vice versa, and is its own complement.¬C[i] p 1 ·
There is a shared tract between sequences and , over theC C1 2
contiguous set of markers , (1) if for alla,… ,b C [i] ∼ C [i] a 1 2
; (2) if there is at least one i for which ; (3)i  b C [i] p C [i] ( ·1 2
if , then and neither is ; and (4) ifa 1 1 C [a 1] ( C [a 1] ·1 2
, then and neither is . Item (1) re-b ! m C [b 1] ( C [b 1] ·1 2
quires that the two sequences have the same allelic state over the
shared tract; item (2) requires that, for at least one position in
the tract, both sequences are deﬁned; and items (3) and (4) require
that the shared tract is maximal. We denote such a shared tract
as .{C ,C }[a,b]1 2
The algorithm is initialized at time (T is incremented asT p 1
we move back in time) by setting to be the set of contemporary,S1
typed sequences. The algorithm proceeds by ﬁnding which co-
alescences, mutations, and recombinations can be performed, de-
termining this according to the rules below. Applying one of these
operations deﬁnes an ancestral population , which is con-ST1
structed from by use of the transitions also described below.ST
The algorithm continues in this way until it arrives at a popu-
lation with only one sequence.
Coalescence.
Rule. If there exist two sequences, and , in such that,C C S1 2 T
for all i, , then and can be coalesced intoC [i] ∼ C [i] C C1 2 1 2
an ancestor.
Transition. where when′ ′S p (S ' {C ,C })∪ {C } C [i] p C [i]T1 T 1 2 1
and otherwise. (By′C [i] ( · C [i] p C [i] (S ' {C ,C })∪1 2 T 1 2
, we mean with the sequences and removed′{C } S C CT 1 2
and the sequence added in.)′C
Mutation.
Rule. If there exists a sequence in and a marker i, where,C S1 T
for all in , we have or , then weC S ' {C } C [i] p ¬C [i] ·2 T 1 2 1
can remove the derived allele ( ) from the population.C [i]1
Transition. , where and′ ′S p (S ' {C })∪ {C } C [i] p ¬C [i]T1 T 1 1
for all .′C [j] p C [j] j ( i1
Recombination.
Rule. When the rules for coalescence and mutation are not
satisﬁed, we must perform a recombination (or a pair of
recombinations) instead. We denote a recombination
breakpoint as , meaning that it occurs between mark-(a,b)
ers a and b. Picking a shared tract from those{C ,C }[a,b]1 2
available in , we aim to put recombinations on the lin-ST
eages of and such that one recombination parent ofC C1 2
and one recombination parent of satisfy the rule forC C1 2
coalescence. To do this, we must put a breakpoint at
if and put a breakpoint at if(a 1,a) a ( 1 (b,b 1) b (
.m
Transition. From the tract , pick (1) a valid break-{C ,C }[a,b]1 2
point , where either or(a,b) (a,b) p (a 1,a) (a,b) p
, and (2) a recombinant sequence , where either(b,b 1) CR
or . Then, ,′ ′C p C C p C S p (S ' {C }) ∪ {C ,C }R 1 R 2 T1 T R 1 2
where for and otherwise,′ ′C [i ] p C [i ] i  a C [i] p ·1 R 1
and for all and otherwise. If′ ′C [i] p C [i] i  b C [i] p ·2 R 2
both and are valid breakpoints (i.e.,(a 1,a) (b,b 1)
and ), we must put the second recombinationa ( 1 b ( m
(taking us to state ) on an appropriate ancestor ofS CT2 1
or . See ﬁgure 1D–1G for an example.C2
These rules deﬁne the constraints on the algorithm that must
be enforced if it is to produce legal ARGs. However, at any stage
of the algorithm, there may be several different coalescences,mu-
tations, or recombinations that satisfy the rules. We choose be-
tween these, using the heuristics below, and the stochastic ele-
ments mean that different ARGs are generated each time the
algorithm is run.
Heuristics. (1) Perform a recombination only if no mutations or
coalescences are possible. (2) If it is possible to add multiple mu-
tations and/or multiple coalescences at the same time, the order
in which these are done is chosen arbitrarily. (3) Coalesce se-
quences only if they have an overlapping region of deﬁned ma-
terial—that is, the two sequences must match for at least one
position that is not . This restriction reﬂects ideas in the se-·
quentially Markovian coalescent-with-recombination model.11
(4) Recombinations are added at the ends of longer shared tracts
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ﬁrst. During the recombination step, we choose a shared tract
such that the base-pair distance between markers a{C ,C }[a,b]1 2
and b is maximized, reﬂecting that longer shared tracts tend to
arise from more-recent recombination events. However, because
this is only a tendency, not absolute, we break this heuristic with
a certain probability (which, throughout this article, is 0.1), and,
in these cases, a randomly selected tract is used to position re-
combination breakpoint(s). (5) The ﬁrst coalescence after a re-
combination is based on the shared segment that was used to
decide the location of that recombination.
Handling Unphased and Missing Data
By extending our algorithm, it is possible to resolve haplotype
phase and impute missing data while constructing an ARG. Han-
dling the missing data is the simpler of the two cases. A missing
character is allowed to coalesce with any other character (0,1, ,·
or another missing character), and, when it coalesces with a state-
known character (0 or 1), the missing character becomes ﬁxed to
that state and this assignment is propagated down the ARG to
the leaves.
Phasing the data is similar, except that a record of the diploid
pairings of chromosomes is kept. A phase-unknown character
may not coalesce with the corresponding phase-unknown char-
acter on its sister chromosome (because the individual is hetero-
zygous at that position). When a phase-unknown character co-
alesces with a state-known character, its phase becomes ﬁxed, as
does the character on its sister chromosome, although to the com-
plement state. When phase-unknown characters from two chro-
mosomes coalesce, these chromosomes and their sisters become
dependent on each other; neither of those chromosomes may
coalesce with the sister of the other one, and, when one of the
chromosomes has a character phase resolved, that character is
also resolved on the other chromosome and to the comple-
ment state on the two sister chromosomes. Of course, many
more than four chromosomes can become involved in such
interdependencies.
Fine-Scale Mapping Using ARGs
An ARG generated as described above deﬁnes a marginal tree for
each chromosome position (ﬁg. 1A–1C). For a given position, the
marginal tree can be extracted from the ARG by tracing the ge-
nealogy of that position back in time from the leaves. When a
recombination is encountered, the genealogy follows the path of
the left recombination parent if the breakpoint is to the right of
the position in question; otherwise, it follows the right recom-
bination parent.
We can test a position for association by seeing whether its
marginal tree has a branch on which we can place a hypothetical
causative mutation that suitably explains the observed disease
states of the genotyped individuals—such as mutation 2 in ﬁgure
1. (Note that, although such a branch extends over an interval
of markers in the ARG, localization is reﬁned by recombination
events lower down the ARG; these change the number of case
and control chromosomes under the branch at each position.
Therefore, our method gives a different score at each marker.)
Our test is as follows: since the true ARG is unknown, we infer
an ensemble of 100 plausible ARGs. These are generated by run-
ning the ARG inference algorithm 100 times, and stochastic
choices made during ARG construction (such as which pairs of
sequences to coalesce ﬁrst) mean that these ARGs are all different.
For each marker, the 100 marginal trees are extracted from the
ARGs. For each marginal tree, hypothetical disease-predisposing
mutations are put on each branch in turn. These cause the case-
control individuals (the leaves of the tree) to be bipartitioned
into those with the mutant allele and those with the ancestral
allele. A test can then be used to detect nonindependence2x
between inferred allelic state and disease state. If there are n
leaves, then there are nonequivalent, nonunary bipartitionsn 3
of a tree, and, hence, test statistics for a tree. Under the2n 3 x
assumption that the region spanned by one tree harbors, at most,
one causative mutation, we take the maximum of these testn 3
statistics, calling this the “best-cut score.” After ﬁnding the best-
cut score for each of the 100 trees, we take the mean, giving an
association score for the marker (this assumes that all the inferred
ARGs are equally likely).
Although we test for nonindependence between alleles and
disease, the test could easily be modiﬁed to test for association
between genotype and disease. Similarly, a regression could be
performed, rather than a test, allowing our method to be ap-2x
plied to quantitative phenotype data. Or we could calculate the
likelihood of the data given the tree, although this would require
an explicit disease andmutationmodel. Also, we need not assume
that there is only one causative mutation on a tree.20
We calculate the statistical signiﬁcance of the mapping score
at each marker—the markerwise P value—by permuting the as-
signments of case and control labels of the individuals and re-
peating the test above. By performance of multiple permutations,
an empirical null distribution is generated from which the P value
can be calculated.27 For P values exceeding the precision of the
permutations, we ﬁt an extreme value distribution to the empir-
ical distribution.28
Since multiple markers are being tested for association, there
is a multiple-testing issue, whichwe can correct for by calculating,
for each marker, an experimentwise P value: the probability that
any of the typed markers show such a strong association signal
by chance. Again, this is done by permutation; after shufﬂing the
case and control labels, the maximum association score of all the
markers is recorded, thus deﬁning an empirical experimentwise
null distribution. Once again, an extreme value distribution can
be ﬁtted, to estimate small P values.
Simulation of Case-Control Studies
To evaluate the performance of our method under a variety of
disease models, we simulated suites of case-control studies. Each
suite contains 50 studies simulated under the same model, which
was parameterized according to (1) the recombination model of
the population from which the cases and controls were sampled,
(2) the tagging SNP (tSNP) ascertainment scheme, (3) whether
the sequences are phased or unphased and the amount ofmissing
data, and (4) the disease model parameters: genotype relative risk,
disease-allele frequency, and size of study.
The case-control studies were sampled from one of two pop-
ulations, which we call “constant” and “hot.” Both populations
contain 20,000 1-Mb chromosome sequences, which were sim-
ulated using the FREGENE forward simulator29 (BARGEN Web
site) and are available from the Margarita Web site. The constant
population was simulated using the simple (i.e., no population
expansion or complex demography) Wright-Fisher model with a
constant recombination rate. The mutation rate was 81.1# 10
per generation per nucletide, and the recombination crossover
rate was per generation per nucleotide. In contrast,82.2# 10
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the hot population was simulated with recombination hotspots.
These were 2 kb in length and accounted for 1% of the length
of the region but 60% of all recombinations. The average recom-
bination crossover rate was the same as before, resulting in re-
combination crossover rates within and between hotspots of
and per bp per generation, respectively.7 96.56# 10 4.44# 10
Gene conversions were also included, with a constant tract length
of 50 bp and average rate across the genome of . Gene71.1# 10
conversions were assigned the same hotspots as crossovers, and
their rates within and between hotspots were and66.56# 10
per bp per generation, respectively. For both popu-84.44# 10
lations, all SNPs with minor-allele frequency (MAF) 0.005 were
recorded (yielding 4,621 SNPs in the constant population and
4,825 SNPs in the hot population).
For each population, tSNPs were selected using three schemes,
as follows.
“Full” ascertainment. A total of 120 chromosomes were sampled
without replacement from the population and were presented
to the tagging program TAGGER.30 (For the constant popula-
tion, 4,235 of the 4,621 SNPs were polymorphic in this sample
and thus were considered for tagging; for the hot population,
4,389 of the 4,825 SNPs were polymorphic). We set TAGGER
to use a maximum tagging distance of 100 kb (the distance
between a tag and the SNPs it tags) and that the tags be designed
for single-marker tests.
5% Ascertainment. This ascertainment is like the full ascertain-
ment, but only SNPs with in the population wereMAF  0.05
considered in the tagging process.
Random. tSNPs were evenly spaced but otherwise were selected
at random from the SNPs with in the population.MAF  0.05
In all three cases, 300 tSNPs were chosen. For full and 5% ascer-
tainments, these were the best 300 tSNPs according to TAGGER.
The disease model for each suite of 50 case-control studies was
speciﬁed by parameters q, , , and , where q isGRR(Aa) GRR(AA) ncc
the frequency of the disease-predisposing allele, is theGRR(Aa)
genotype relative risk of the heterozygote, is the ge-GRR(AA)
notype relative risk of the mutant homozygote, and is thencc
number of case chromosome sequences (which, in our simu-
lations, is the same as the number of control sequences).
was varied between 1.4 and 2.4, was set toGRR(Aa) GRR(AA)
(an additive effect), q was varied between 0.022#GRR(Aa) 1
and 0.20, and was varied between 500 and 3,000. To calculatencc
the penetrances of each genotype at a disease locus, it was also
necessary to specify the population prevalence of the disease; this
was set to 1% for all simulated studies.
To simulate a case-control study, the following process was
used:
Step 1. From one of the FREGENE populations (all SNPs with
), a SNP with MAF between andMAF  0.005 q 0.005
was picked at random to be causative.q 0.005
Step 2. Two sequences (a diploid individual) were picked at ran-
dom (with replacement) from the population.
Step 3. The individual was assigned to the case set or control set
according to the probability of having the disease, given
his or her genotype at the causative SNP.
Step 4. Steps 2 and 3 were repeated until case sequences andncc
control sequences were sampled.ncc
Step 5. Only the 300 tSNPs were output.
Resampling from the population is not ideal, but we are limited
by the size of population, which it is computationally feasible to
simulate. The resampling may be thought of as performing an
additional round of Wright-Fisher evolution with a sudden in-
crease in population size or as there being unidentiﬁed consan-
guinity in the study. This approach has been used elsewhere.30
Results
We have implemented the algorithm as a program called
“Margarita” and have assessed it with both simulated and
real data sets involving thousands of individuals typed for
hundreds of markers across megabase-scale regions. The
performance of a mapping method may be measured ac-
cording to three criteria: (1) power—the probability of ob-
taining a signiﬁcant association signal in a region around
a causative polymorphism, (2) localization—how ac-
curately one can estimate the position of an untyped caus-
ative polymorphism, and (3) interpretation—the ability
to estimate properties of an untyped causative polymor-
phism (in addition to its position), such as its frequency,
which can then guide further investigation.
The power and localization of Margarita across a range
of disease models were compared with those of two other
methods: the single-marker test and the CLADH hap-2x
lotype-clustering method.15 Single-marker and haplotype-
based tests are those most commonly used in practice;
coalescent methods such as LATAG20 are not computa-
tionally feasible for the scale of data we consider here. The
single-marker test is often used in practice, and, for our2x
simulations, we have selected tSNPs that capture much of
the population variation, meaning that this test is not as
“naive” as it may be when markers are chosen at random.
From the many available haplotype-based methods, we
chose to compare our method with CLADH because it is
designed to be applied to megabase-scale regions, is com-
putationally feasible, and has been shown to perform well
against similar methods.31
To illustrate how our method can be used to interpret
and dissect an association signal, we analyzed data from
Ueda et al.’s study32 of association between CTLA4 (MIM
123890) and Graves disease (MIM 275000).
Results for a Simulated Suite of Case-Control Studies
We simulated case-control studies typed for 300 markers
across a 1-Mb region, as described in the “Methods” sec-
tion. These correspond to ﬁne-mapping studies where one
has detected or suspects a causative polymorphism in the
region andwishes to ﬁnely localize and interpret that signal.
We ﬁrst compared Margarita, CLADH, and the test,2x
using a suite of 50 case-control studies with parameters
, , , and ,GRR(Aa) p 2 GRR(AA) p 3 q p 0.04 n p 2,000cc
sampled from the constant population with the full as-
certainment tSNP set, and with the use of the true phased
haplotype sequences with no missing data. The associa-
tion structure for one of those studies is shown in ﬁgure
2A.
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Figure 2. Analysis of a suite of case-control studies with disease parameters , , , andGRR(Aa) p 2 GRR(AA) p 3 q p 0.04 n pcc
, sampled from the constant population with the full ascertainment tSNP set. A, Association structure for a simulated case-control2,000
study. denotes the position of the (untyped) causative SNP. B,Probability of there being a signiﬁcant association within an interval
around the causative SNP. C and D, Markerwise P values at the marker closest to the causative SNP for each of the 50 studies. E,
Cumulative distribution of distances between the association peak and the causative SNP. F, Distribution of estimated allele frequency.
All Margarita P values for the simulated studies were
calculated by performing 10,000 permutations, and P val-
ues !.0001 were estimated by ﬁtting extreme value dis-
tributions. Analysis of one case-control study (4,000 hap-
lotype sequences of 300 SNPs) by use of Margarita on a
2.8-GHz Pentium IV processor requires 3–4 min to con-
struct 1 ARG and 6 h to perform the mapping test with
10,000 permutations on 100 ARGs. The mapping test for
Margarita is for marginal trees, which potentially change
at each marker; therefore, we took the location of the
typed marker to be the point location of the test. However,
the branch that best segregates the cases and controls will
be linked to that marker and may not correspond to it.
When using CLADH, the user is required to specify the
number of SNPs in each haplotype window. We tried the
range of window widths used in the CLADH article,15 and
we report the best results obtained (using windows of size
5). All CLADH P values were calculated with 10,000 per-
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Figure 3. Marginal tree correlation versus LD for part of ENCODE2r
region 7p15.2 from the phase I HapMap.38 Tree correlation is mea-
sured as the proportion of the nonequivalent, nonunaryn 3
bipartitions of the leaves of each tree (deﬁned by cutting
branches) that are shared between trees at different positions.
mutations, and we took the location of the typed SNP
closest to the center of the window as the point location
of the test. We now consider the mapping performance
measures of power, localization, and interpretation, in
turn.
Power.—To determine power, we deﬁned a window
around the causative SNP and calculated the proportion
of case-control studies with a signiﬁcant signal ( )P .05
within that window. Figure 2B shows the probability of
detecting a markerwise and experimentwise signiﬁcant as-
sociation within a window around the untyped causative
SNP. We are unable to report the experimentwise signiﬁ-
cances for CLADH, because it does not calculate these.
When one considers markerwise signiﬁcance (top three
lines in ﬁg. 2B), the test and CLADH have greater power2x
than that of Margarita for windows 125 kb around the
causative SNP. However, when one corrects for multiple
testing, Margarita has greater power than that of the 2x
test (lower two lines). This difference arises because Mar-
garita’s tests at adjacent SNPs are more strongly correlated
through shared ancestry than are those of the test (see2x
ﬁg. 3), reducing the effective number of independent tests
across the region.
In ﬁgure 2C and 2D, we report the markerwise P values
for the test that is closest (according to its point location)
to the untyped causative SNP in each of the 50 case-con-
trol studies. The P values attained by Margarita are typi-
cally stronger than those obtained by the other methods.
We have compared the false-positive rates of the three
methods by counting the number of associations with
markerwise at a distance 1250 kb from the untypedP .05
causative SNP. An association is counted when the signal
breaks below the 0.05 cutoff and then returns above it.
The mean number of such false-positive results for a case-
control study from this suite is 0.70 for Margarita, 6.16
for CLADH, and 10.48 for the test. This may explain,2x
in part, the apparent difference in markerwise power at
longer distances (ﬁg. 2B).
Localization.—By localization, we mean how accurately
we can estimate the position of the causative SNP. For each
of the methods, we take the point location of the test with
the strongest markerwise P value as the estimate of caus-
ative SNP location. Figure 2E shows that our method gives
better localization than do CLADH and the test for this2x
suite of studies.
Interpretation.—In studies where the causative SNPs are
untyped, it is useful to estimate properties of those SNPs,
thus guiding the design of subsequent studies. For ex-
ample, an estimate of causative-allele frequency (which
one can also obtain with haplotype-clustering methods17)
can be used to calculate the sample size required to achieve
signiﬁcance. To estimate this, we take the ensemble of
marginal trees at the marker closest to the causative SNP
and record the branch (bipartition) of each tree that shows
the strongest disease association—we call this the “best
cut.” For each tree, an estimate of causative-allele fre-
quency can be obtained by calculating the frequency of
chromosomes in the general population that fall under
the best-cut branch.
Figure 2F shows the distribution of causative-allele fre-
quencies as estimated by the ARGs constructed for this
suite (causative-allele frequency 0.04). The median esti-
mate is 0.036. Note that we report only frequency esti-
mates from studies with a signiﬁcant association signal.
Additionally, we obtain a sample of estimated ancestral
haplotypes from which the causative allele may have
arisen (data not shown).
Results across a Range of Simulated Disease Models
So far, we have reported only the performances of the
three methods for one suite of case-control studies—that
is, under one disease model. In this section, we explore a
range of models by varying each parameter (either GRR(Aa),
the causative-allele frequency q, or the study size )ncc
in turn while ﬁxing the others at “default” values of
, , , andGRR(Aa) p 2 GRR(AA) p 2#GRR(Aa) 1 q p 0.04
. In all these simulations, we used the constantn p 2,000cc
population with the full tSNP ascertainment scheme.
Figure 4A compares the power of Margarita and the
power of the test to detect an experimentwise signiﬁ-2x
cant ( ) association within 100 kb of the untypedP .05
causative SNP. CLADH is excluded from this comparison
because it does not calculate experimentwise P values. In
a comparison of experimentwise P values, Margarita out-
performs the test.2x
Figure 4B shows the localization performance of the
three methods. For the majority of disease models, Mar-
garita outperforms both the test and CLADH.2x
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Figure 4. Power, localization, and interpretation for a range of disease models. Each point on the X-axis corresponds to a suite of
50 studies. Each of the disease parameters is varied between suites, whereas the other parameters are held at “default” values of
, , , and . All studies are sampled from the constant population with theGRR(Aa) p 2 GRR(AA) p 2# GRR(Aa) 1 q p 0.04 n p 2,000cc
full ascertainment tSNP set. A, Probability of an experimentwise signiﬁcant signal within 100 kb of the causative SNP (calculated as
the proportion of studies in each suite that meet this criterion). B, Probability that the association peak is within 100 kb of the
causative SNP. C, Estimated causative-allele frequency versus true frequency q.
Finally, ﬁgure 4C shows themedian estimated causative-
allele frequency for a range of suites with varying causa-
tive-allele frequency (we report only estimates from stud-
ies with a signiﬁcant association signal). We compared the
performance of Margarita with that of a simple haplotype
approach. For this, we considered all windows of length
up to 10 SNPs around the causative polymorphism. We
tested each haplotype allele for association with the dis-
ease and used the frequency of the most strongly associ-
ated haplotype allele to estimate the frequency of the caus-
ative polymorphism. Margarita has a slight downwardbias
in its estimate, but, nevertheless, it is reasonable and out-
performs the simple haplotype approach just described,
which has a signiﬁcant upward bias and a higher variance.
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Figure 5. Localization for different data, populations, and tSNP models. A, Performance on a suite of case-control studies with
, , , and , sampled from the constant population and with the full ascertainment tSNPGRR(Aa) p 2 GRR(AA) p 3 q p 0.04 n p 2,000cc
set. Margarita is applied to this suite under three scenarios: when the data are phased, when they are unphased, and when they are
phased but have 10% missing data. B, Performance on a suite of case-control studies sampled from the hot population (and with
, , , and ). Performance is compared using three different tSNP ascertainment schemesGRR(Aa) p 2 GRR(AA) p 3 q p 0.04 n p 2,000cc
(described in the “Methods” section).
Results across a Range of Simulated Population Models
and Ascertainment Schemes
For our ﬁnal set of simulations, the disease model was
ﬁxed to , , , andGRR(Aa) p 2 GRR(AA) p 3 q p 0.04 n pcc
, whereas the data quality, population model, and2,000
SNP ascertainment scheme were varied.
In ﬁgure 5A, we examine the effect of missing and un-
phased data on the performance of our method. For this
ﬁgure, the same suite of case-control studies (sampled
from the constant population and with the full tSNP as-
certainment scheme) were used, but with the sample out-
put either as phased haplotype sequences, unphased ge-
notype sequences, or phased sequences with 10% missing
data. These results show that Margarita is robust against
both these complications. We did not compare Margarita
with CLADH because the latter requires phasedhaplotypes
with no missing data.
In ﬁgure 5B, we evaluate the performance of Margarita
for case-control studies sampled from a population sim-
ulated using a recombination hotspot model (the hot pop-
ulation described in the “Methods” section). Under this
scenario, we see a performance increase for the test,2x
compared with under the scenario of using the constant
population (compare ﬁg. 5B with 5A). However, it still
performs less well than Margarita. The test has increased2x
performance because recombination hotspots give rise to
blocks of strong LD, resulting in tSNPs that capture more
of the population variation.
In ﬁgure 5B, we also compare the effect of the tSNP
ascertainment scheme on mapping performance. The same
suite of case-control studies was used, but the samples were
“typed” using each of the three tSNP selection schemes
described in the “Methods” section. tSNP selection based
on less complete data (speciﬁcally, when the causative
polymorphism is not included in the data used to select
tSNPs) results in signiﬁcantly reduced performance of the
test but has less of an effect on Margarita’s performance.2x
Furthermore, the SNP ascertainment scheme that is best
for the test (full ascertainment) is not necessarily the2x
best for Margarita (which seems to prefer markers with
frequency 0.05). For clarity, we did not plot the results
from CLADH in ﬁgure 5; although consistent with the
previous studies, the performance of CLADH tends to fall
between Margarita and the test.2x
Results for Real Data
In this section, we analyze data from a ﬁne-mapping study
of association between polymorphisms in the region of
the CTLA4 gene and an autoimmune disorder,32 showing
how our method can be used to dissect an association
signal. In the study byUeda et al.,32 a 300-kb region (CD28-
CTLA4-ICOS) was genotyped for 108 SNPs in 384 individ-
uals with Graves disease and 652 controls. In their anal-
ysis, three association peaks were identiﬁed; moving from
left to right in ﬁgure 6A, these peaks are at SNPs MH30,
CT60, and CTBC217_1. By performing a regression anal-
ysis, they concluded that the causative variant is more
likely to be around the CT60 peak than around the others.
Furthermore, CT60 was found to be correlated to the ex-
pression of CTLA4 mRNA isoforms.
Since the data are unphased and there are missing ge-
notype data, we used the ability of Margarita to infer these
(in inferring 100 ARGs, we obtain 100 different phase res-
olutions, thus marginalizing over phase uncertaintywhen
performing the mapping test). However, the data being
unphased will present a hurdle for mapping methods that
require phased haplotype sequences. One way to over-
come this problem is to run a phasing algorithm33 on the
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Figure 6. Analysis of the CTLA4 data. A, Association structure of the region. B, Distribution of estimated causative-allele frequency,
by use of marginal trees at CT60. C, Test for allelic heterogeneity, by calculation of the proportion of inferred marginal trees at each
position for which a chromosome appears under the branch that best segregates the cases and controls. D, Association structure for
a subset of the CTLA4 data—only those chromosomes with the protective CT60 allele.
data and then pass the result to the mapping method, as
though it is the true phase resolution.34 To examine the
effect of this, we also ran Margarita on the “best” phase
resolution of the data after applying one run of the pro-
gram PHASE.35
Figure 6A shows that CT60 has the strongest disease
association in our analysis (when using both the PHASEd
and the unphased data), which agrees with the analysis
by Ueda et al.32 All Margarita P values in this section were
calculated by performing up to 1 million permutations.
Margarita used on the unphased data gives a stronger
association signal at CT60 ( ) than does Mar-6P ≈ 2# 10
garita used on the PHASEd sequences ( ). This5P ≈ 2# 10
result agrees with that of Morris et al.,34 who similarly
show that a two-stage approach results in a loss of power
compared with the handling of genotypes directly and
marginalizing over unknown phase. Both Margarita anal-
yses have lower signiﬁcance than that of the test (2x P ≈
), which would be expected if CT60 is indeed61.6# 10
the causative polymorphism, a hypothesis that can be ex-
plored further by using the ARGs to dissect the association
signal.
Figure 6B gives the distribution of the estimated sus-
ceptibility-allele frequency in the general population (cal-
culated using the observation that Graves disease has pop-
ulation prevalence of 0.5%). The mean estimate for the
causative allele in the cases and controls is 65% and 54%,
respectively, corresponding to the G allele of CT60 (63%
and 52% in cases and controls, respectively). This suggests
that the bulk of the association signal at CT60 is due to
susceptibility caused by CT60, or something extremely
tightly linked to it.
However, in 43% of the inferred ARGs for the unphased
data, Margarita is able to ﬁnd internal branches of the
marginal tree at CT60 that segregate the cases and controls
with test P values ∼107, with the strongest being2x
∼109; this suggests a second causative polymorphism.We
therefore used the inferred ARGs to test explicitly for al-
lelic heterogeneity. We took the 100 marginal trees for
each marker and counted the number of times each chro-
mosome appeared under the branch corresponding to
the best partitioning of cases and controls—the best-cut
branch. When a chromosome is under the best-cut
branch, it means that, if there is a disease-causing allele
at that position, then it is likely that the chromosome
possesses it. Figure 6C shows this analysis for an illustra-
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tive sample of 167 case chromosomes (with phase inferred
on the ARGs). For each marker and chromosome, the in-
tensity of the plot represents the proportion of trees for
which the chromosome is under the best cut. Case chro-
mosomes 131–167 show a different pattern than do the
others. They occur less frequently under the best cut at
CT60 and more frequently under the best cut at CT53 and
CTBC358, whereas case chromosomes 1–130 appear fre-
quently under the best cut at CT60 but infrequently under
the best cut at CT53 and CTBC358. There are other case
chromosomes not associated with any of these loci (not
shown). To test whether CT53 or CTBC358 are also sus-
ceptibility loci (or linked to susceptibility loci), we strat-
iﬁed the case-control population in three ways, as follows.
Only those chromosomes with the protective allele at
CT60.—We took the PHASEd chromosomes and removed
all those with the CT60 susceptibility allele, running our
analysis on the remaining 282 case chromosomes and 620
controls with the protective allele (ﬁg. 6D).When the pop-
ulation is stratiﬁed in this way, the association signals at
MH30 and CTBC217_1 collapse into the background, sug-
gesting that the association signals at those locations are
due to LD with CT60. Furthermore, there is an association
peak at CT53 (markerwise test ; Margarita2 5x P ≈ 5# 10
). By use of Margarita, the estimated frequency4P ≈ 2# 10
of the causative allele (92% in the cases and 82% in the
controls) matches that of the A allele at CT53 in this sub-
population (93% in the cases and 83% in the controls),
suggesting that the A allele confers susceptibility on this
CT60 background.
Only those chromosomes with the susceptibility allele at
CT60.—When we condition on the CT60 susceptibility
allele, we obtain 486 case chromosomes and 684 control
chromosomes. In this subpopulation, CT53 has a weak
signal of association with the disease (markerwise test2x
; Margarita ). In contrast to the previousP ≈ .023 P ≈ .016
stratiﬁcation, the A allele at CT53 is less frequent in the
cases (2%) than in the controls (5%), suggesting that A
may be protective on this haplotypic background. This
reversal of the effect of CT53 dependent on CT60 status
may explain why CT53 is not detected in simple analyses
using the full data.
Only those individuals who are homozygous for the CT60
protective allele.—To check that the CT53 association is not
due to some spurious signal resulting from the selection
of chromosomes on the basis of their inferred haplotype
phase, we took the genotype sequences homozygous for
the CT60 protective allele and ran Margarita on these un-
phased sequences. There are 102 case chromosomes and
300 controls, which give a weaker but still signiﬁcant sig-
nal of association (markerwise test ; Margarita2x P ≈ .012
). As expected, on this background the A allele ofP ≈ .013
CT53 is the susceptibility allele.
These results suggest epistasis between CT60 and CT53,
with the A allele at CT53 conferring susceptibility on a
CT60 protective background but being protective on a
CT60 susceptibility background. To test explicitly for epis-
tasis between CT60 and CT53, we performed a logistic
regression test for interaction36,37 and obtained forP ≈ .004
interaction effects over and above single-marker effects.
Given the small samples sizes of these subpopulations,
further genotyping in more samples is required to deter-
mine whether the observed signal atCT53 is a true positive
or an artifact of the data. Nevertheless, we have shown
that it is possible to interrogate real data by use of inferred
ARGs.
Discussion
Advantages of the Method
Association studies rely on LD to summarize the recom-
bination history. However, LD statistics (such the mea-2r
sure of LD, which is strongly related4 to the test) are2x
not pure measures of recombination distance; they are
affected by other factors, such as the relative timing of
mutation events and nonrandom mating patterns. This
confounds our ability to map disease loci.
Shifts in marginal tree topology, however, are entirely
dependent on the positions of observable recombinations,
so the degree of correlation between marginal trees is a
better measure of (observable) recombination distance.
Figure 3 illustrates this and helps explain the enhanced
performance of our method over the test. Compared2x
with , the correlation between adjacent trees is (1) tighter2r
into the diagonal, giving ﬁner localization and fewer false-
positive results caused by distant markers being stochas-
tically correlated; (2) stronger, because, when the causative
SNP is untyped, there is a stronger association signal from
adjacent markers, giving greater power; and (3) smoother
in its decay—because tests are more correlated, we observe
an improvement in experimentwise signiﬁcance.
Furthermore, the inferred ARGs can be used to make
useful inferences about causative polymorphisms in ad-
dition to their position. Taking the branches of the mar-
ginal trees that show the strongest clustering of cases be-
neath them, we can estimate the frequencies of causative
alleles, the ancestral haplotypes on which they arose, and
which cases are caused by each allele, giving a clustering
of the cases and possibly identifying allelic, locus, or phe-
notypic heterogeneity. These three estimates are particu-
larly useful for designing follow-up studies and provide
important advantages of our approach.
Compared with haplotype-clustering methods, our ap-
proach naturally handles rare haplotypes and unphased
data and does not require the speciﬁcation of nonrecom-
bining haplotype blocks. It also gives more-precise ﬁne
mapping. Using ARGs is not the same as using haplotype-
based methods; recombinations subsequent to the for-
mation of the haplotype interval can give additional
mapping information, which our method uses. Compared
with other ARG-based methods, it is faster. We are able to
build ARGs for large data sets, involving thousands of in-
dividuals typed for hundreds of SNPs, and it remains com-
putationally feasible when the data are unphased. By use
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of a cluster of processors, it is feasible to window the anal-
ysis over the whole genome and thus apply this approach
to whole-genome case-control studies.
We now consider some other potential features of our
approach that have not been tested in this article. Our
method could be adapted to handle allelic heterogeneity
by allowing multiple causative mutations on each mar-
ginal tree when the mapping test is performed, as in
LATAG20.
Along with various types of heterogeneity, cryptic pop-
ulation substructure is another confounder of many pop-
ulation genetic analyses. One may, however, expect the
subpopulations to tend to cluster in the ARG,whichmakes
identiﬁcation of substructure and analyses that allow for
this possible.
Because our method can handle missing and unphased
data by resolving both on the ARG, it may be possible to
combine samples from different association studies that
do not necessarily have overlapping markers. The missing
SNPs in each study could be imputed, thus merging the
studies in a principled way—according to population his-
tory. In particular, it should be possible to include addi-
tional densely typed samples, such as the HapMap sam-
ples.38 This would allow imputed estimation in the cases
and controls of the values of SNPs that had been typed
in the additional samples and allow explicit testing of di-
rect association with those SNPs as well as the tree-based
analysis described here.
Similarly, it may be possible to combine and analyze
data from multiple family-based linkage studies. Known
relationships between individuals could be enforced as
rules in the ARG inference algorithm, whereas the foun-
ders of pedigrees could be allowed to coalesce and recom-
bine according our standard ARG inference rules. In this
way, it may be possible to extract more information from
previous studies.
Limitations of the Method
By avoiding inference under the coalescent-with-recom-
bination model, we have discarded an understood prob-
abilistic framework that lends itself naturally to a Bayesian
formulation. Consequently, we do not attach probabilities
to the inferred ARGs but consider them all to be equally
likely. Nor have we provided a strong deﬁnition of what
“plausible” ARG inference means. The heuristics described
in the “Methods” section suggest some aspects of why our
inferred ARGs are plausible, but providing justiﬁcation is
that the inferred ARGs work for disease mapping.
A second limitation, which is probably true of all the
more sophisticated mapping methods, is that, when the
causative mutations are typed, our method is unlikely to
provide a signiﬁcant mapping advantage (in terms of lo-
calization and power) over a single-marker test. We might
expect this to be typically the case in the future, if it be-
comes routine to fully resequence individuals.39 Never-
theless, resequencing would not render ARG inference
redundant, since we suggest that there are potential ap-
plications to other population genetic analyses, such as
the identiﬁcation of selection, population substructure,
and estimation of the ages of alleles.
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Web Resources
The URLs for data presented herein are as follows:
BARGEN, http://www.ebi.ac.uk/projects/BARGEN (for download-
ing the FREGENE simulator)
Margarita, http://www.sanger.ac.uk/Software/analysis/margarita
(for downloading the Java program Margarita, plus high-reso-
lution versions of the ﬁgures from this article)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for CTLA4 and Graves disease)
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